Clinical Trial

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

Study acronym: E-REVRI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and lenalidomide.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-16; most recent amendment 2026-06-12.
Status change: Not Yet Recruiting → Recruiting 2026-02-09
Trial Details
NCT Number NCT06931652
Lead Sponsor The Lymphoma Academic Research Organisation
Collaborators: AbbVie
Conditions Primary CNS Lymphoma (PCNSL)
Enrollment 60 participants
Start Date 2025-09-22
Primary Completion 2028-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-15